tiprankstipranks
Trending News
More News >
Basilea Pharmaceutica (CH:BSLN)
:BSLN
Switzerland Market

Basilea Pharmaceutica (BSLN) Financial Statements

Compare
2 Followers

Basilea Pharmaceutica Financial Overview

Basilea Pharmaceutica's market cap is currently CHF607.56M. The company's EPS TTM is CHF4.7; its P/E ratio is 7.63; Basilea Pharmaceutica is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is CHF2.03. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total RevenueCHF 208.54MCHF 157.63MCHF 147.76MCHF 148.12MCHF 127.63M
Gross ProfitCHF 169.86MCHF 130.84MCHF 120.96MCHF 124.05MCHF 103.58M
Operating IncomeCHF 61.18MCHF 19.20MCHF 16.34MCHF 1.17MCHF -23.26M
EBITDACHF 63.13MCHF 23.18MCHF 26.21MCHF 6.72MCHF -2.24M
Net IncomeCHF 77.59MCHF 10.45MCHF 12.15MCHF -6.83MCHF -14.72M
Balance Sheet
Cash & Short-Term InvestmentsCHF 120.71MCHF 59.90MCHF 86.57MCHF 149.95MCHF 167.28M
Total AssetsCHF 257.76MCHF 173.29MCHF 220.85MCHF 247.27MCHF 229.79M
Total DebtCHF 111.67MCHF 128.61MCHF 187.14MCHF 218.96MCHF 242.32M
Net DebtCHF -9.03MCHF 68.71MCHF 150.57MCHF 164.00MCHF 186.71M
Total LiabilitiesCHF 176.76MCHF 183.29MCHF 241.56MCHF 305.87MCHF 331.84M
Stockholders' EquityCHF 81.00MCHF -10.00MCHF -20.71MCHF -58.61MCHF -102.05M
Cash Flow
Free Cash FlowCHF 72.65MCHF 13.21MCHF 3.75MCHF -32.88MCHF -56.40M
Operating Cash FlowCHF 74.36MCHF 14.24MCHF 7.06MCHF -32.02MCHF -54.13M
Investing Cash FlowCHF -1.01MCHF -1.03MCHF 91.65MCHF 3.58MCHF -34.96M
Financing Cash FlowCHF -13.16MCHF -57.30MCHF -45.25MCHF 16.64MCHF 45.07M
Currency in CHF

Basilea Pharmaceutica Earnings and Revenue History

Basilea Pharmaceutica Debt to Assets

Basilea Pharmaceutica Cash Flow

Basilea Pharmaceutica Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis